Program
nirsevimab
Also written as “Nirsevimab”, “MEDI8897” and “MEDI8897 Intravenous”.
Its studies are mostly in Respiratory Syncytial Virus Infections, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 90 open or running | phase 3since May 21, 2019 | Apr 3, 2014 | none ahead |
| Sanofi | 21 open or running | phase 4since Jul 31, 2025 | Jun 24, 2022 | none ahead |
Also a collaborator on its studies: iqvia-rds-inc, iqvia-pty-ltd and iqvia-rds-shanghai-co-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 3, 2014First study: phase 1 study in Respiratory Syncytial Virus InfectionsNew to AstraZenecaAstraZeneca · NCT02114268 · 342 enrolled · United States
- Oct 17, 2014Phase 1 study in Respiratory Syncytial VirusAstraZeneca · NCT02290340 · 151 enrolled · United States, Chile, South Africa
- Aug 22, 2016Phase 2 study in Respiratory Syncytial Virus InfectionsAstraZeneca · NCT02878330 · 1,453 enrolled · United States, Argentina, Australia and more
- May 21, 20192 phase 3 studies in Respiratory Syncytial Virus InfectionsAstraZeneca · NCT03959488, NCT03979313
- Jun 30, 2020Phase 2 study in Respiratory Syncytial Virus InfectionsAstraZeneca · NCT04484935 · 100 enrolled · United States, Belgium, Japan and more
- Apr 8, 2021Phase 1 study in Evaluate PK ProfileAstraZeneca · NCT04840849 · 24 enrolled · China
- Oct 7, 2021Phase 3 study in Lower Respiratory Tract InfectionAstraZeneca · NCT05110261 · 800 enrolled · China
- Jun 24, 2022Sanofi's first study: phase 3 study in RSV ImmunizationNew to SanofiSanofi · NCT05437510 · 8,057 enrolled · France, Germany, United Kingdom
- Jul 13, 2023Phase 3 study in Respiratory Syncytial Virus InfectionsAstraZeneca · NCT06042049 · 33 enrolled · Japan
- Jul 31, 2025Phase 4 study in RSV ImmunizationSanofi · NCT07109297 · 110 enrolled · India
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Fusion glycoprotein F0 inhibitor”ChEMBL 37, by rule
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07109297RSV Immunization · India | 4 | Active, not recruiting | Sanofi | Jun 30, 2026 | 110 |
| NCT06042049Respiratory Syncytial Virus Infections · Japan | 3 | Completed | AstraZeneca | Jul 24, 2025 | 33 |
| NCT05437510RSV Immunization · France, Germany, United Kingdom | 3 | Completed | Sanofi | Mar 27, 2024 | 8,057 |
| NCT05110261Lower Respiratory Tract Infection · China | 3 | Completed | AstraZeneca | Nov 24, 2025 | 800 |
| NCT04840849Evaluate PK Profile · China | 1 | Completed | AstraZeneca | Nov 18, 2021 | 24 |
| NCT04484935Respiratory Syncytial Virus Infections · United States, Belgium, Japan and more | 2 | Completed | AstraZeneca | Feb 17, 2023 | 100 |
| NCT03979313Respiratory Syncytial Virus Infections · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Mar 11, 2021 | 3,012 |
| NCT03959488Respiratory Syncytial Virus Infections · United States, Austria, Belgium and more | 3 | Completed | AstraZeneca | May 3, 2021 | 925 |
| NCT02878330Respiratory Syncytial Virus Infections · United States, Argentina, Australia and more | 2 | Completed | AstraZeneca | Jul 17, 2018 | 1,453 |
| NCT02290340Respiratory Syncytial Virus · United States, Chile, South Africa | 1 | Completed | AstraZeneca | Sep 28, 2016 | 151 |
| NCT02114268Respiratory Syncytial Virus Infections · United States | 1 | Completed | AstraZeneca | Jun 2015 | 342 |
How it is read
Names in the registry
- “Nirsevimab”, 5 entries
- “MEDI8897”, 3 entries
- “MEDI8897 Intravenous”, 3 entries
- “MEDI8897 Intramuscular”, 2 entries
- “nirsevimab”, 1 entry
Conditions, from the studies’ own filings
- Respiratory Syncytial Virus Infections, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.